Emmett Schmidt

Emmett Schmidt

Company: Merck & Co

Job title: Vice President, Lead External Collaborations Project Team Global Clinical Development


Breakfast Panel: Bridging the TKI vs. Immunotherapy Conversations in NSCLC 9:00 am

Discussing stage of cancer, combinations, and order of treatment rationale for the well-validated immunotherapies and TKIs in early lines Exploring shifts of focus between the immune system of the patient (immunotherapies) and the biology of the tumor (tyrosine kinase inhibitors) How can we combine insights from both immune system markers and tumor markers, to be…Read more

day: Day Two

Synergy is a 4 Letter Word: Lessons of Independent Action as an Explanation for the Efficacy of Cancer Clinical Combination Therapies 4:30 pm

– Immuno oncology drugs are failing at an unprecedented rate, perhaps because too much reliance has been placed on pre-clinical thinking about synergy – Based on the mathematics of Independent Action, synergy has not been seen in any immuno oncology registration trials to date – To progress development of combinations of ADC and PD-1 immune…Read more

day: Day One

Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors 12:30 pm

Understanding the different current comparators and benchmarks Exploring the differences in PD-1 naïve and PD-1 progressors Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar Discussing whether with late-line in-effectivity, how you know it won’t work in early line? Considering the health authorities’ standards on the matterRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.